Replikins explains how an analysis of gene structures in the dengue virus led to the development of a vaccine candidate
Replikins Ltd, the company that first identified a group of peptides called Replikins, has announced that one of its studies on the genetic structure of the dengue virus has been instrumental in the development of their synthetic dengue vaccine candidate.
The Replikins study analysed data on all strains of the dengue virus, and the analysis showed that many of the genetic structures conserved between different strains of the virus are replikins.
The findings allowed for Replikins Ltd to develop a dengue vaccine which targets the conserved genetic structures across different strains of the virus, much like how the H5N1 flu vaccine works.
Currently, there is no approved vaccine for dengue fever, and the WHO estimates that around 390 million people a year contract the virus.
Read more about it here: Genetic analysis of dengue leads to synthetic vaccine